Janus Henderson Group PLC Schedule 13G passive stakes

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed a combined beneficial ownership of 14.3% in Mereo BioPharma Group PLC's American Depositary Shares as of March 31, 2025.

Janus Henderson Group plc and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have filed an amended Schedule 13G disclosing beneficial ownership of 18.6% of Monopar Therapeutics Inc.'s common stock.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 7.4% in Ascendis Pharma A/S as of March 31, 2025.

Janus Henderson Group PLC has filed a Schedule 13G, reporting a beneficial ownership of 8.5% of Travere Therapeutics, Inc.'s common stock.

Janus Henderson Group plc has filed a Schedule 13G, reporting a beneficial ownership of 5.7% of Maze Therapeutics, Inc.'s common stock as of March 31, 2025.

Janus Henderson Group plc has disclosed a passive 5.0% ownership stake in Inspired Entertainment, Inc., holding 1,354,929 shares of common stock.

Janus Henderson Group plc has filed a Schedule 13G, reporting a 5.1% beneficial ownership stake in TYRA Biosciences, Inc. as of March 31, 2025, held for investment purposes.

Janus Henderson Group plc has filed a Schedule 13G, reporting a passive beneficial ownership of 6.4% of Gildan Activewear Inc.'s common stock.

Janus Henderson Group PLC has filed a Schedule 13G, revealing a 6.5% beneficial ownership stake in Verona Pharma PLC's American Depositary Shares.

Janus Henderson Group PLC has filed a Schedule 13G, revealing a 7.6% beneficial ownership stake in Praxis Precision Medicines, Inc. as of March 31, 2025.

Janus Henderson Group PLC has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 7,900 shares, representing 0.0% of Cargo Therapeutics, Inc.'s common stock.

Janus Henderson Group PLC has filed an amended Schedule 13G, disclosing a 2.2% beneficial ownership stake in IMMUNOME INC, held for investment purposes in the ordinary course of business.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 3.6% beneficial ownership stake in Zai Lab Ltd's common stock as of March 31, 2025.

Janus Henderson Group plc has filed an Amendment No. 9 to Schedule 13G, reporting a passive beneficial ownership of 4.3% in Blackbaud, Inc. as of March 31, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Revvity Inc.'s common stock, held for investment purposes.

Janus Henderson Group PLC has filed an amended Schedule 13G, revealing a beneficial ownership of 10.0% of ICU Medical, Inc.'s common stock as of April 30, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, revealing a 10.1% beneficial ownership stake in Mirum Pharmaceuticals, Inc. as of April 30, 2025.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a beneficial ownership of 11.3% in Vaxcyte, Inc.'s common stock as of April 30, 2025.

Janus Henderson Group plc, through its affiliates, has disclosed a beneficial ownership of 16.0% in Bright Minds Biosciences Inc.'s common stock as of March 31, 2025, according to an amended Schedule 13G filing.

Janus Henderson Group plc and its affiliate have reported a combined beneficial ownership of 10.3% in Protara Therapeutics, Inc.'s common stock, held for investment purposes.

Janus Henderson Group PLC and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 12.7% in Consensus Cloud Solutions, Inc. as of December 31, 2024.

Janus Henderson Group plc has filed an Amendment No. 8 to Schedule 13G, disclosing its beneficial ownership of 8.7% of Akero Therapeutics Inc's common stock as of December 31, 2024.

Janus Henderson Group PLC has filed an Amendment No. 5 to its Schedule 13G, disclosing a 10.3% beneficial ownership stake in Ardelyx Inc. as of December 31, 2024.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 5.4% beneficial ownership stake in Tenax Therapeutics, Inc. as of December 31, 2024.

Janus Henderson Group plc and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 11.3% of Benitec Biopharma Inc.'s common stock as of December 31, 2024.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 5.2% beneficial ownership stake in Revvity Inc. as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 5.3% beneficial ownership stake in Sensient Technologies Corporation as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, disclosing its beneficial ownership of 5.3% of Rentokil Initial plc's Common Stock as of December 31, 2024.

Janus Henderson Group PLC has filed an amended Schedule 13G, disclosing a 5.4% beneficial ownership stake in Ligand Pharmaceuticals Incorporated as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, revealing a 5.5% beneficial ownership stake in Walker & Dunlop, Inc. as of December 31, 2024.